Cargando…

Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1

BACKGROUND: Parvovirus H-1 (H-1PV) infects and lyses human tumor cells including melanoma, hepatoma, gastric, colorectal, cervix and pancreatic cancers. We assessed whether the beneficial effects of chemotherapeutic agents or targeted agents could be combined with the oncolytic and immunostimmulator...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moehler, Markus, Sieben, Maike, Roth, Susanne, Springsguth, Franziska, Leuchs, Barbara, Zeidler, Maja, Dinsart, Christiane, Rommelaere, Jean, Galle, Peter R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234202/ https://www.ncbi.nlm.nih.gov/pubmed/22029859 http://dx.doi.org/10.1186/1471-2407-11-464

Ejemplares similares

Oncolytic Virotherapy as Emerging Immunotherapeutic Modality: Potential of Parvovirus H-1
por: Moehler, Markus, et al.
Publicado: (2014)

Preclinical Testing of an Oncolytic Parvovirus: Standard Protoparvovirus H-1PV Efficiently Induces Osteosarcoma Cell Lysis In Vitro
por: Geiss, Carsten, et al.
Publicado: (2017)

Rational Combination of Parvovirus H1 With CTLA-4 and PD-1 Checkpoint Inhibitors Dampens the Tumor Induced Immune Silencing
por: Goepfert, Katrin, et al.
Publicado: (2019)

Preclinical Testing of an Oncolytic Parvovirus in Ewing Sarcoma: Protoparvovirus H-1 Induces Apoptosis and Lytic Infection In Vitro but Fails to Improve Survival In Vivo
por: Lacroix, Jeannine, et al.
Publicado: (2018)

A novel scalable, robust downstream process for oncolytic rat parvovirus: isoelectric point-based elimination of empty particles
por: Leuchs, Barbara, et al.
Publicado: (2017)

Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer cells
por: Heinrich, Bernd, et al.
Publicado: (2013)

Oncolytic effects of parvovirus H-1 in medulloblastoma are associated with repression of master regulators of early neurogenesis
por: Lacroix, Jeannine, et al.
Publicado: (2014)

Pediatric and Adult High-Grade Glioma Stem Cell Culture Models Are Permissive to Lytic Infection with Parvovirus H-1
por: Josupeit, Rafael, et al.
Publicado: (2016)

Oncolytic parvoviruses: from basic virology to clinical applications
por: Marchini, Antonio, et al.
Publicado: (2015)

Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity
por: Angelova, Assia L., et al.
Publicado: (2017)

Tumor Selectivity of Oncolytic Parvoviruses: From in vitro and Animal Models to Cancer Patients
por: Angelova, Assia L., et al.
Publicado: (2015)

The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers
por: Angelova, Assia L., et al.
Publicado: (2017)

Improved Killing of Human High-Grade Glioma Cells by Combining Ionizing Radiation with Oncolytic Parvovirus H-1 Infection
por: Geletneky, Karsten, et al.
Publicado: (2010)

Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses
por: Ungerechts, Guy, et al.
Publicado: (2016)

Activation of a Helper and Not Regulatory Human CD4+ T Cell Response by Oncolytic H-1 Parvovirus
por: Moralès, Olivier, et al.
Publicado: (2012)

Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas
por: Li, Junwei, et al.
Publicado: (2013)

Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial
por: Geletneky, Karsten, et al.
Publicado: (2017)

Human Retrotransposons and the Global Shutdown of Homeostatic Innate Immunity by Oncolytic Parvovirus H-1PV in Pancreatic Cancer
por: Neulinger-Muñoz, Matthias, et al.
Publicado: (2021)

TLR-9 Contributes to the Antiviral Innate Immune Sensing of Rodent Parvoviruses MVMp and H-1PV by Normal Human Immune Cells
por: Raykov, Zahari, et al.
Publicado: (2013)

Oncolytic H-1 Parvovirus Hijacks Galectin-1 to Enter Cancer Cells
por: Ferreira, Tiago, et al.
Publicado: (2022)

Chemovirotherapy: combining chemotherapeutic treatment with oncolytic virotherapy
por: Binz, Eike, et al.
Publicado: (2015)

Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol
por: Geletneky, Karsten, et al.
Publicado: (2012)

Parvoviruses-tools to fine-tune anticancer immune responses
por: Grekova, Svitlana P., et al.
Publicado: (2012)

Parvoviruses Cause Nuclear Envelope Breakdown by Activating Key Enzymes of Mitosis
por: Porwal, Manvi, et al.
Publicado: (2013)

Immune System Stimulation by Oncolytic Rodent Protoparvoviruses
por: Angelova, Assia, et al.
Publicado: (2019)

Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs
por: Braidwood, Lynne, et al.
Publicado: (2013)

Emerging role of Natural killer cells in oncolytic virotherapy
por: Bhat, Rauf, et al.
Publicado: (2015)

Oncolytic H-1 Parvovirus Enters Cancer Cells through Clathrin-Mediated Endocytosis
por: Ferreira, Tiago, et al.
Publicado: (2020)

Oncolytic H-1 parvovirus binds to sialic acid on laminins for cell attachment and entry
por: Kulkarni, Amit, et al.
Publicado: (2021)

Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells
por: Sei, Shizuko, et al.
Publicado: (2009)

Stability and safety key factors of the oncolytic protoparvovirus H-1 from manufacturing to human application
por: Frehtman, Veronika, et al.
Publicado: (2023)

Vesicular Egress of Non-Enveloped Lytic Parvoviruses Depends on Gelsolin Functioning
por: Bär, Séverine, et al.
Publicado: (2008)

Canine Parvovirus and Its Non-Structural Gene 1 as Oncolytic Agents: Mechanism of Action and Induction of Anti-Tumor Immune Response
por: Arora, Richa, et al.
Publicado: (2021)

Vesicular Transport of Progeny Parvovirus Particles through ER and Golgi Regulates Maturation and Cytolysis
por: Bär, Séverine, et al.
Publicado: (2013)

Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade
por: Marchini, Antonio, et al.
Publicado: (2016)

Evaluation of Chemotherapeutic Agents
por: Engstrom, W. W.
Publicado: (1949)

NK-cell-dependent killing of colon carcinoma cells is mediated by natural cytotoxicity receptors (NCRs) and stimulated by parvovirus infection of target cells
por: Bhat, Rauf, et al.
Publicado: (2013)

Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study
por: Marchini, Antonio, et al.
Publicado: (2019)

Mutations in the Non-Structural Protein-Coding Sequence of Protoparvovirus H-1PV Enhance the Fitness of the Virus and Show Key Benefits Regarding the Transduction Efficiency of Derived Vectors
por: Hashemi, Hamidreza, et al.
Publicado: (2018)

Parvovirus-Based Combinatorial Immunotherapy: A Reinforced Therapeutic Strategy against Poor-Prognosis Solid Cancers
por: Angelova, Assia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_01qhkjpda12qlo95acgfnsbsmv